ATF-Long (adenine nucleotides) tablets 10 mg. №40

active ingredients: 1 tablet contains ATP-long in terms of 100% substance with a total content of adenine nucleotides 6.3 mg – 10 mg;

excipients : powdered sugar; lactose; magnesium stearate silicon dioxide colloidal.

Pills.

Basic physical and chemical properties: tablets of a round shape with a flat surface with bevelled edges, with a chamfer and a notch on one side, white.

cardiac drugs. ATX code C01E B10.

ATF-Long (adenine nucleotides) 10 mg. is a drug of a new class of substances – mixed-ligand coordination compounds with macroergic phosphates, the molecule of which consists of adenosine-5’triphosphate (ATP), the amino acid histidine, magnesium and potassium salts and has a pharmacological effect characteristic only of it, not inherent in any single chemical component (ATP, histidine, K, Mg++).

ATF-Long (adenine nucleotides) 10 mg. affects metabolic processes in the myocardium, normalizes energy metabolism, the activity of ion transport systems of cell membranes, lipid composition of membranes, the activity of membrane-bound enzymes, improves the antioxidant system of myocardial protection, has an anti-ischemic, membrane-stabilizing effect, antiarrhythmic effect in supraventricular tachycardia.

The drug has an energy-saving effect due to the inhibition of the activity of the 5′-nucleotidase enzyme, which is responsible for the rate of hydrolysis of energy substrates. ATP-LONG® prevents structural and functional damage to the plasma membranes of cardiomyocytes, ensuring the preservation of the quantitative and qualitative composition of membrane lipids, inhibiting the activity of membrane-bound phospholipases. ATP-LONG® inhibits the intensity of lipid peroxidation (LPO) processes, thereby reducing the accumulation in membranes of the products of hydrolysis and peroxidation of fatty acid phospholipids, lysophospholipids, which are characterized by pronounced detergent properties and the ability to cause disturbances in the contractile and rhythmic activity of the heart during ischemia. In the case of experimental myocardial ischemia, the drug increases the activity of Na + -K + -ATPase and Ca 2+ -Mg2 + -ATPase and the calcium-binding potential of the membrane. ATP-LONG® improves central and peripheral hemodynamics, coronary circulation, normalizes myocardial contractility, increases physical performance. In conditions of ischemia, the drug reduces myocardial oxygen consumption, activates the functional state of the heart, increases cardiac output, which helps to reduce the frequency of angina attacks and shortness of breath during physical exertion.

ATF-Long (adenine nucleotides) 10 mg. restores normal sinus rhythm in patients with paroxysmal supraventricular tachycardia, with blinking and atrial flutter, and also reduces the activity of ectopic rhythm foci (atrial and ventricular extrasystoles).

ATF-Long (adenine nucleotides) 10 mg. normalizes the concentration of potassium and magnesium in tissues, reduces the concentration of uric acid.

Use in complex therapy:

• Ischemic heart disease, stable and unstable angina pectoris, angina pectoris and angina pectoris with registered vasospasm;
• Past myocardial infarction, postinfarction myocardial syndrome (diffuse and focal cardiosclerosis), ischemic cardiomyopathy;
• Heart rhythm disturbances;
• Neurocirculatory asthenia, cardiogenic neurosis;
• Cardiomyopathy;
• Myocarditis;
• fatigue syndrome.

• Hypersensitivity to the drug and its components;
• acute myocardial infarction;
• cardiogenic and other types of shock;
• obstructive diseases of the bronchopulmonary system;
• severe forms of bronchial asthma;
• sinoatrial blockade;
• blockade II-III degree;
• hyperkalemia, hypermagnesemia;
• hemorrhagic stroke.